[{"from": "human", "value": "Provide a brief overview of this molecule. [C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=C][C][=Branch1][P][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][Branch1][C][F][Branch1][C][F][F][N][C][=N][C][=C][C][C][C][=C][Branch1][#Branch1][C][Ring1][=Branch1][=N][Ring1][#Branch2][N][Branch1][#Branch2][N][=C][Ring1][#Branch1][C][=Branch1][C][=O][N][C][C][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis."}]